The Pharma Data

JULY 12, 2021

These data include results from a late-breaking presentation from a Phase 2a study evaluating the safety and pharmacokinetics (PK) of once-monthly (QM) oral islatravir for pre-exposure prophylaxis (PrEP) through 24 weeks. Safety and Pharmacokinetics of Islatravir in Study Participants with Severe Renal Insufficiency. Abstract 2361.

Pharmacokinetics 52

Pharmacokinetics Clinical Trials Trials Treatment 52

Drug Target Review

SEPTEMBER 25, 2024

Analysis of transcriptional changes using RNA sequencing further confirmed that TT125-802 suppresses key non-oncogene resistance mechanisms including transcriptional networks around stemness, epithelial-mesenchymal transition (EMT), and transforming growth factor beta (TGFβ) signalling. Available from: [link] 8.Boni

Small Molecule 105

Small Molecule Therapies Regulations Treatment 105

The Pharma Data

JULY 6, 2021

Fitusiran is an investigational, subcutaneously administered small interference RNA therapy in development for the treatment of people with hemophilia A or B, with or without inhibitors and has the potential to transform treatment as it would be the only prophylactic therapy with as few as six injections per year.

Therapies 52

Therapies Pharmacokinetics Treatment RNA 52

The Pharma Data

JANUARY 21, 2021

In the ATLAS study, CABENUVA met the primary endpoint for noninferiority (the proportion of participants with plasma HIV-1 RNA ?50 50 copies per milliliter [c/mL] at Week 48), with a comparable number of patients receiving either CABENUVA or their daily current antiretroviral regimen (CAR) having an HIV-1 RNA level ?50

FDA Approval 52

FDA Approval Treatment RNA FDA 52

New Drug Approvals

JANUARY 31, 2024

citation needed ] The pharmacokinetic properties of obeldesivir and improved was first published by Chinese researchers in May 2022. 2-NTP , an analog of ATP, inhibits the SARS-CoV-2 RNA-dependent RNA polymerase replication and transcription of viral RNA. Tchesnokov, E. Woolner, E.; Porter, D. 295 (20): 6785–6797.

RNA 52

RNA Science Treatment Pharmacokinetics 52

Codon

APRIL 2, 2023

Read A new DNA polymerase variant, called RT-KTq I614Y, can directly detect RNA modifications, including pseudouridine (Ψ) and queuosine (Q). By combining this new variant with standard sequencing methods, it’s possible to identify RNA modifications in a really simple way. Nucleic Acids Research. Communications Biology.

DNA 52

DNA RNA Engineering Licensing 52

The Pharma Data

NOVEMBER 5, 2020

The companies planned to initiate a randomized, multi-center, open-label Phase 2 clinical trial that explores the safety, pharmacokinetics, and antiviral activity of ABI-H0731, RNAi therapeutic AB-729 and an NrtI. AB-729 is an RNA interference (RNAi) therapeutic.

Virus 40

Virus Clinical Trials Therapies Pharmacokinetics 40

Drug Target Review

JULY 1, 2024

Using the 10X Genomics Chromium platform, we conducted ribonucleic acid (RNA) sequencing on the midbrain’s PAG region in animals treated with SRP-001, ApAP and a vehicle control, focusing on gene expression changes related to pain processing. It addresses both acute and chronic pain, avoiding the addiction risks associated with opioids.

Treatment 59

Treatment Clinical Trials Therapies Molecular Biology 59

The Pharma Data

APRIL 22, 2023

Results from a Phase 1 study evaluating the safety, tolerability, and pharmacokinetics (PK) of obeldesivir, previously known as GS-5245, a novel investigational oral compound being developed by Gilead for the treatment of SARS-CoV-2 infection, showed obeldesivir reaches expected therapeutic plasma concentrations for the treatment of COVID-19.

Hospitals 40

Hospitals Treatment Virus Pharmacokinetics 40

Alta Sciences

APRIL 17, 2024

Oligonucleotide-Based Techniques Most oligonucleotide therapies act through antisense mechanisms and are directed against various RNA species. Read The Altascientist , “Nonclinical Studies in Cell and Gene Therapy”. 3.

Drug Development 52

Drug Development Treatment FDA Approval Drugs 52

New Drug Approvals

SEPTEMBER 29, 2024

In addition, older dogs had bacterial antigens and ribosomal RNA in their brains, consistent with systemic infection seen in humans. The pharmacokinetic profiles of COR388 in AD and controls were reported to be similar. Findings Two Phase 1 trials of atuzaginstat were completed by June 2019. All volunteers with AD had P.

Small Molecule 62

Small Molecule DNA Disease Trials 62

New Drug Approvals

JANUARY 9, 2024

As a TFIIH subunit, CDK7 phosphorylates the CTD (Carboxy-Terminal-Domain) of the largest subunit of RNA polymerase II (pol II). In addition to CDK7, other CDKs have been reported to phosphorylate and regulate RNA pol (II) CTD. 13, 261-91, 1997). 1004-1014, 2004). Oct 1 5;24(20):2303-16, 2010; Blazek et al.,

Production 62

Production DNA RNA Regulations 62

Codon

FEBRUARY 23, 2025

.” In 1974, Wolfram Ostertag , a German geneticist at the Max Planck Institute, explored whether zidovudine could block retroviruses , which carry RNA, and use a reverse transcriptase enzyme to convert it into DNA before integrating into the host genome.

Clinical Trials 70

Clinical Trials Virus Vaccine DNA 70